WO2025017212 - UDP-GLUCOSE CERAMIDE GLUCOSYLTRANSFERASE SYNTHASE (UGCG) INHIBITORS IN THE TREATMENT OF CANCER
National phase entry is expected:
Publication Number
WO/2025/017212
Publication Date
23.01.2025
International Application No.
PCT/EP2024/070717
International Filing Date
22.07.2024
Title **
[English]
UDP-GLUCOSE CERAMIDE GLUCOSYLTRANSFERASE SYNTHASE (UGCG) INHIBITORS IN THE TREATMENT OF CANCER
[French]
INHIBITEURS DE SYNTHASE DE GLUCOSYLTRANSFÉRASE DE CÉRAMIDE D'UDP-GLUCOSE (UGCG) DANS LE TRAITEMENT DU CANCER
Applicants **
KATHOLIEKE UNIVERSITEIT LEUVEN
Inventors
BELOTSERKOVSKY, Jaroslav
DEHAIRS, Jonas
DE LAAT, Vincent
IDKOWIAK, Jakub
SWINNEN, Johannes
TALEBI, Ali
VANDERHOYDONC, Frank
Priority Data
23186690.6
20.07.2023
EP
23210507.2
17.11.2023
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2729 | |
| EPO | Filing, Examination, Granting | 17427 | |
| Japan | Filing, Examination, Granting | 2709 | |
| South Korea | Filing, Examination, Granting | 3117 | |
| USA | Filing, Examination, Granting | 7140 |
Total:
33,122
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The invention relates to chemotherapy agents such as gemcitabine and and inhibitors of UDP-glucose ceramide glucosyltransferase synthase (UGCG) such as miglustat, lucerastat, sinbaglustat, eliglustat, ibiglustat, for use in the treatment of cancers, such as pancreatic cancers.[French]
L'invention concerne des agents de chimiothérapie tels que la gemcitabine et des inhibiteurs de synthase de glucosyltransférase de céramide d'udp-glucose (UGCG) tels que le miglustat, le lucérastat, le sinbaglustat, l'éliglustat, l'ibiglustat, destinés à être utilisés dans le traitement de cancers, tels que des cancers du pancréas.